Standardization of the red cell product

Area of Science:

• Transfusion Medicine
• Hematology

Background:

• Red cell products are sourced from whole blood and apheresis donations.
• Whole blood products exhibit significant variability in red cell content (potency), while apheresis products are more standardized.
• Current transfusion practices use non-standard units, which is unscientific.

Purpose of the Study:

• To evaluate the benefits of standardizing red cell product content.
• To explore methods for improving the predictability of clinical outcomes in transfusion recipients.
• To propose alternatives to the current unscientific unit-based prescription system.

Main Methods:

• Analysis of variability in red cell content from whole blood and apheresis donations.
• Modeling the impact of standardized red cell content on clinical outcomes.
• Evaluating methods for measuring and labeling red cell product potency.

Main Results:

• Whole blood products can vary twofold in red cell content; apheresis products have ~6% variation.
• Standardized red cell products enhance predictability of clinical outcomes.
• Potency labeling allows for recipient-defined product selection.

Conclusions:

• Standardizing red cell content or labeling potency can optimize transfusion practices.
• This approach can lead to reduced over-transfusion, particularly in low-volume recipients.
• Adopting standardized or potency-labeled red cell products represents a move towards more scientific transfusion medicine.